All articles tagged with #phase 1 trial
In a 14-day phase 1 trial, healthy volunteers taking TLC-2716 showed up to 38.5% lower triglycerides and up to 61% lower remnant cholesterol after meals, by inhibiting LXRα activity in the liver and gut. The oral drug was safe and well tolerated, suggesting potential for treating cardiometabolic disease, but longer studies in overweight/obese individuals with poor lipid profiles are needed to confirm benefits.
OCS-05, a neuroprotective treatment candidate for multiple sclerosis (MS) or other causes of optic nerve inflammation, has shown a favorable safety and pharmacological profile in healthy volunteers, according to Phase 1 trial data. A Phase 2 trial is now evaluating OCS-05’s safety and effectiveness in people with acute optic neuritis due to MS, myelin oligodendrocyte glycoprotein antibody-associated disease, or an unknown cause. The trial will assess changes in eye health, visual acuity, and overall disability.